Immutep Positive Preliminary Topline Results in Head & Neck Cancer

 

• Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the study
• Data collection, cleaning, and analysis continues and additional data from TACTI-003 (Cohorts A & B), including complete response rate, will be released in H1 CY2024

https://www.globenewswire.com/news-release/2024/04/24/2868564/0/en/Immutep-Announces-Positive-Preliminary-Topline-Results-from-TACTI-003-Cohort-B.html